phenothiazine has been researched along with Alzheimer Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Arndt, HD; Gaube, F; Raztsou, I; Robaa, D; Rohrbach, MM; Sager, H; Schätz, B; Schwarthoff, S; Tischer, N; Winckler, T | 1 |
| Cai, J; Chen, H; Dong, C; Du, Z; Li, L; Li, Y; Meunier, B; Yan, L; Zhang, W | 1 |
| Chu, JC; Hsin, LW; Hsu, KC; Huang, WJ; Lee, HS; Lin, CH; Lin, TE; Liu, CI; Tseng, HJ; Wang, AH; Wang, HC | 1 |
| Aksinenko, AY; Aliev, G; Bachurin, SO; Barreto, GE; Boltneva, NP; Grigoriev, VV; Lushchekina, SV; Makhaeva, GF; Serebryakova, OG; Sokolov, VB; Vikhareva, EA | 1 |
| Cisek, K; Honson, NS; Jensen, JR; Kuret, J | 1 |
| Akoury, E; Biernat, J; Gajda, M; Mandelkow, E; Pickhardt, M; Zweckstetter, M | 1 |
| Conrad, S; Darvesh, KV; Darvesh, S; Gomez, G; Martin, E; Mataija, D; McDonald, RS; Walsh, R | 1 |
7 other study(ies) available for phenothiazine and Alzheimer Disease
| Article | Year |
|---|---|
Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Phenothiazines; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship | 2021 |
Development of novel theranostic agents for in vivo amyloid imaging and protective effects on human neuroblastoma cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Humans; Male; Mice, Inbred C57BL; Mice, Transgenic; Neuroprotective Agents; Optical Imaging; Phenothiazines; Plaque, Amyloid; Protein Aggregation, Pathological; Theranostic Nanomedicine | 2019 |
Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.
Topics: Acetylation; Alzheimer Disease; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Drug Design; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Molecular Docking Simulation; Neurites; Neuroprotective Agents; Oxidative Stress; Phenothiazines; Structure-Activity Relationship; Tubulin | 2021 |
Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease.
Topics: Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Drug Design; Enzyme Activation; Humans; Models, Chemical; Molecular Docking Simulation; Phenothiazines; Protein Binding; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2015 |
Ligand polarizability contributes to tau fibril binding affinity.
Topics: Alzheimer Disease; Benzothiazoles; Binding Sites; Humans; Indoles; Ligands; Oxindoles; Phenothiazines; Protein Binding; tau Proteins; Thiazoles | 2011 |
Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Cysteine; Disease Models, Animal; Humans; Magnetic Resonance Spectroscopy; Methylene Blue; Oxidation-Reduction; Phenothiazines; Protein Binding; tau Proteins | 2013 |
Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine.
Topics: Acetylcholine; Alzheimer Disease; Amides; Amyloid; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Neurotransmitter Agents; Phenothiazines; Structure-Activity Relationship; Substrate Specificity | 2007 |